Complications d’un dispositif intraveineux implantable pour chimiothérapie dans les cancers des voies aérodigestives supérieures

Hoareau-Gruchet, F.; Rtail, R.; Sulaj, H.; Khirnetkina, A.; Reyt, É.; Righini, Christian

doi:10.1016/j.aorl.2009.02.005

Cited by 10 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We carried out a retrospective, single-center study that included 305 TIVAPs over 57,324 catheter days. The overall incidence of complications was 2.95%, which is significantly lower than that reported by Narducci et al (16.1%) [ 5 ], Zhou et al (13.2%) [ 9 ], and Hoareau-Gruchet et al (7.4%) [ 10 ]. This result suggests that even immediate use of chemoports after implantation does not increase the complication rate, making it safe for long-term use.…”

Section: Discussionmentioning

confidence: 54%

Safety of immediate use of totally implantable venous access ports in adult patients with cancer: a retrospective single-center study

Lee

Hur

Kim

et al. 2021

Korean J Clin Oncol

View full text Add to dashboard Cite

Purpose: Totally implantable venous access ports (TIVAPs) can be used long-term for safe administration of intravenous drugs. TIVAP complications include catheter-related infections, venous thrombosis, extravasation, TIVAP migration, and pain. The relationship between the timing of the first chemotherapy administration after port implantation and complications is controversial. This study aimed to investigate the safety of immediate use of TIVAPs and the associated risk factors for complications.Methods: Between January 2016 and December 2018, 305 patients (median age, 53 years; 256 women) who underwent TIVAP placement at our institution were included. Chemotherapy was administered within 2 days of implantation. A retrospective analysis of patients’ clinical data was performed to investigate catheter days and complications of TIVAPs.Results: Overall, 305 patients were evaluated over 57,324 catheter days (median, 168 catheter days; interquartile range, 105). The median interval between placement and first use of TIVAPs was 0.98 days. The overall morbidity rate was 2.95%. Nine complications occurred in nine patients, including TIVAP-related infection (4), pain (2), port occlusion (1), thrombosis (1), and scar disunion (1), of which five required port removal (1.64%). The median number of catheter days before complications occurred was 61 (range, 10–457 days; interquartile range, 51). No complications occurred within 7 days of implantation. Body mass index was an independent risk factor for TIVAP-related complications in the Cox proportional hazards model (multivariable analysis: hazard ratio, 1.221; 95% confidence interval, 1.054–1.414; P = 0.008).Conclusion: This study suggests the safe long-term use of TIVAPs following their immediate chemotherapy administration within 2 days of implantation.

show abstract

Section: Discussionmentioning

confidence: 54%

Safety of immediate use of totally implantable venous access ports in adult patients with cancer: a retrospective single-center study

Lee

Hur

Kim

et al. 2021

Korean J Clin Oncol

View full text Add to dashboard Cite

show abstract

Morbidity-mortality conference for adverse events associated with totally implanted venous access for cancer chemotherapy

Merle

Marini

Fiore

et al. 2015

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Evaluation of the position of the central venous catheter tip of implantable venous access devices in the occurrence of postoperative thrombotic and non-thrombotic complications

Hamri,

Pop,

Mauriac

et al. 2024

Support Care Cancer

View full text Add to dashboard Cite

Background: The catheter tip of totally implanted venous access devices (TIVAD) is a risk factor for postoperative complications. The study aim was to assess the early (EC) and late complications (LC) associated with the position of the catheter tip in patients with cancer.Methods: We reviewed cancer patients who had a TIVAD placed in 2020. EC (<90 days), LC (>90 days) and risk factors for TIVAD-associated complications were assessed. The vertical mismatch of the catheter tip compared to a "ideal position": >10mm below the carina and >20 mm belowthe right main bronchus (RMB) was assessed on post-implantation chest x-ray. Results:301 patients were included, with a median time of port follow at 9.4 months. All TIVADs were inserted via the internal jugular vein (IJV). The mean distance between the catheter tip and the carina or RMB was 21.3 mm and6.63 mm respectively. In total, 11.3% TIVADs developed EC and 5.6% had LC. An association was found between the position of the catheter tip from the carina (≤ 10mm vs > 10mm) and the occurrence of EC (18.3% vs 8.6%, p=0.01) and for the insertion site (left IJV vs right IJV) (19.1% vs 9.0% p=0.02). In multivariate analysis, left IJV insertion (OR 2.76), and a catheter tip located ≤ 10 mm below the carina (OR 2.71) were the signi cant independent risk factors of EC.Conclusions: TIVAD catheter tip located at less than 10 mm below the carina and a left-side inserted catheter are at higher risk of short-term complications.

show abstract

Complications d’un dispositif intraveineux implantable pour chimiothérapie dans les cancers des voies aérodigestives supérieures

Cited by 10 publications

References 17 publications

Safety of immediate use of totally implantable venous access ports in adult patients with cancer: a retrospective single-center study

Safety of immediate use of totally implantable venous access ports in adult patients with cancer: a retrospective single-center study

Morbidity-mortality conference for adverse events associated with totally implanted venous access for cancer chemotherapy

Evaluation of the position of the central venous catheter tip of implantable venous access devices in the occurrence of postoperative thrombotic and non-thrombotic complications

Contact Info

Product

Resources

About